Canaan Files 13G/A for CDTX Showing 0 Shares Owned

Canaan XII L.P. and Canaan Partners XII LLC filed Amendment No. 1 to Schedule 13G reporting that, as of June 30, 2025, neither reporting person beneficially owns any shares of Cidara Therapeutics, Inc. common stock (CUSIP 171757206).

Rhea-AI Filing Summary

Canaan XII L.P. and Canaan Partners XII LLC filed Amendment No. 1 to Schedule 13G reporting that, as of June 30, 2025, neither reporting person beneficially owns any shares of Cidara Therapeutics, Inc. common stock (CUSIP 171757206). The filing lists each filer’s jurisdiction of organization and principal business address and states the holders have 0 sole or shared voting and dispositive power, representing 0.0% of the class.

Positive

• Clear disclosure that both reporting persons beneficially own 0 shares and hold 0.0% of the class
• Identification provided for each reporting person including jurisdiction and principal business address
• Certification and signatures included, affirming the filing's statements

Negative

• None.

Insights

Financial Analyst

TL;DR: The filing discloses zero beneficial ownership by two affiliated investment entities, indicating no present equity stake.

The document clearly states that both Canaan XII L.P. (Cayman Islands) and Canaan Partners XII LLC (Delaware) report 0 shares beneficially owned in Cidara Therapeutics as of June 30, 2025, and 0.0% of the class. For investors, this is a factual ownership disclosure rather than an operational or financial update; it does not indicate transactions, holdings, or changes in control.

Corporate Governance Expert

TL;DR: This Schedule 13G/A is an ownership clarification showing no beneficial interest by the filers.

The filing includes the required certifications and signatures and identifies reporting persons and addresses. It affirms that the securities were not acquired to influence control. The disclosure meets reporting form requirements by stating voting/dispositive powers and percentage ownership explicitly as zero.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Schedule 13G/A filed by Canaan XII L.P. and Canaan Partners XII LLC for CDTX state?

The filing states that as of June 30, 2025 both reporting persons beneficially own 0 shares of Cidara Therapeutics common stock, representing 0.0% of the class.

Who are the reporting persons listed on the CDTX Schedule 13G/A?

The reporting persons are Canaan XII L.P. (Cayman Islands) and Canaan Partners XII LLC (Delaware).

What voting and dispositive powers do the filers report on CDTX?

The filers report 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power.

Does the Schedule 13G/A indicate the filers acquired shares to influence control of CDTX?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What address is listed for the persons filing the Schedule 13G/A for CDTX?

The principal address listed for the filing persons is 2765 Sand Hill Road, Menlo Park, California 94025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CIDARA THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE PER SHARE

(Title of Class of Securities)

171757206

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Canaan XII L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Canaan Partners XII LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CIDARA THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121
Item 2.
(a)	Name of person filing: (i) Canaan XII L.P., a Cayman Islands limited partnership; and (ii) Canaan Partners XII LLC, a Delaware limited liability company.
(b)	Address or principal business office or, if none, residence: 2765 Sand Hill Road, Menlo Park, California 94025
(c)	Citizenship: See Item 2(a) above.
(d)	Title of class of securities: COMMON STOCK, $0.0001 PAR VALUE PER SHARE
(e)	CUSIP No.: 171757206
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2025, none of the Reporting Persons may be deemed to beneficially own any shares of Common Stock of the Issuer.
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Canaan XII L.P.

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	08/14/2025

Canaan Partners XII LLC

Signature:	/s/ Nancy Levenson
Name/Title:	Nancy Levenson, Attorney-in-Fact
Date:	08/14/2025